TMDX vs YBGJ: stock comparison and AI forecast
Transmedics Group, Inc. (TMDX) and Yubo International Biotech Ltd (YBGJ) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
TMDX Transmedics Group, Inc.
- Market Cap
- $2.39B
- P/E Ratio
- 18.4x
- Size
- mid-cap
- AI Forecast
YBGJ Yubo International Biotech Ltd
- Price
- $0.01 -35.7% · 6M
- Market Cap
- n/a
- P/E Ratio
- –
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- Both companies share the SEC industry classification Electromedical & Electrotherapeutic Apparatus.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | TMDX | YBGJ |
|---|---|---|
| Market Cap | $2.39B | – |
| P/E Ratio | 18.39x | – |
| P/B Ratio | 4.34x | – |
| EPS | $3.75 | $-0.01 |
| Book Value/Share | $15.88 | – |
| Revenue/Share | $20.98 | – |
| FCF/Share | $1.29 | – |
Profitability & Margins
| Metric | TMDX | YBGJ |
|---|---|---|
| ROE | 26.2% | – |
| ROA | 9.5% | – |
| ROIC | 6.3% | – |
| Gross Margin | 58.6% | – |
| Operating Margin | 11.9% | – |
| Net Margin | 19.9% | – |
| EBT Margin | 10.1% | – |
| Tax Rate | -96.2% | 0.0% |
Financial Health
| Metric | TMDX | YBGJ |
|---|---|---|
| Current Ratio | 4.53x | 0.18x |
| Quick Ratio | 4.15x | 0.17x |
| D/E Ratio | 1.76x | – |
| Financial Leverage | 2.76x | – |
| Interest Coverage | 2.0x | 7298.4x |
| Working Capital | $540M | -$3M |
Cash Flow
| Metric | TMDX | YBGJ |
|---|---|---|
| Operating Cash Flow | $112M | -$780K |
| Free Cash Flow | $45M | – |
| Capital Spending | -$68M | – |
| OCF Growth YoY | -36.9% | – |
| FCF Growth YoY | -63.0% | – |
| FCF/Sales | 6.1% | – |
| CapEx/Sales | 9.3% | – |
Operational Efficiency
| Metric | TMDX | YBGJ |
|---|---|---|
| Asset Turnover | 0.48x | – |
| Receivables Turnover | 6.3x | 0.1x |
| Inventory Turnover | 5.2x | 0.2x |
| Fixed Assets Turnover | 1.9x | 0.7x |
| Days Sales Outstanding | 58 days | 4079 days |
| Days Inventory | 71 days | 2162 days |
| Payables Period | 12 days | 113947 days |
| Cash Conversion Cycle | 116 days | -107706 days |
Income Statement
| Metric | TMDX | YBGJ |
|---|---|---|
| Total Revenue | $728M | $10K |
| Operating Income | $86M | -$1M |
| Net Income | $144M | -$920K |
| R&D Expense | $106M | – |
| SG&A Expense | $234M | – |
| Cost of Goods Sold | $301M | $0.00M |
Dividend & Shareholder Information
| Metric | TMDX | YBGJ |
|---|---|---|
| Shares Outstanding | 35M | – |
| Net Income Growth | 57.4% | – |
| EPS Growth | 51.8% | – |
TMDX vs YBGJ: stock comparison and AI forecast
Which one does Intratio's AI model rank higher, TMDX or YBGJ?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.